These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11057774)

  • 1. Adjuvant chemotherapy for non-organ confined disease after radical cystectomy.
    Tekin A; Ozen H
    Int Urol Nephrol; 2000; 32(1):59-62. PubMed ID: 11057774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder.
    Sternberg CN; Pansadoro V; Calabro F; Marini L; van Rijn A; Carli PD; Giannarelli D; Platania A; Rossetti A
    Ann Oncol; 1999 Nov; 10(11):1301-5. PubMed ID: 10631456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant CMV chemotherapy plus radical cystectomy in locally advanced bladder cancer: the impact of pathologic response on long-term results.
    Scattoni V; Bolognesi A; Cozzarini C; Francesca F; Grasso M; Galli L; Torelli T; Campo B; Villa E; Rigatti P
    Tumori; 1996; 82(5):463-9. PubMed ID: 9063525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.
    Freiha F; Reese J; Torti FM
    J Urol; 1996 Feb; 155(2):495-9; discussion 499-500. PubMed ID: 8558644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy.
    Soloway MS; Lopez AE; Patel J; Lu Y
    Cancer; 1994 Apr; 73(7):1926-31. PubMed ID: 8137219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement.
    Stöckle M; Wellek S; Meyenburg W; Voges GE; Fischer U; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    Urology; 1996 Dec; 48(6):868-75. PubMed ID: 8973669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
    Choueiri TK; Jacobus S; Bellmunt J; Qu A; Appleman LJ; Tretter C; Bubley GJ; Stack EC; Signoretti S; Walsh M; Steele G; Hirsch M; Sweeney CJ; Taplin ME; Kibel AS; Krajewski KM; Kantoff PW; Ross RW; Rosenberg JE
    J Clin Oncol; 2014 Jun; 32(18):1889-94. PubMed ID: 24821883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
    Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic chemotherapy for muscle invasive bladder cancer.
    Ondrus D; Hornák M; Bárdos A; Ondrus B
    Neoplasma; 1994; 41(5):263-8. PubMed ID: 7854496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy for invasive bladder carcinoma: disease outcome and bladder preservation and relationship to local tumor response.
    Hatcher PA; Hahn RG; Richardson RL; Zincke H
    Eur Urol; 1994; 25(3):209-15. PubMed ID: 8200403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
    Grossman HB; Natale RB; Tangen CM; Speights VO; Vogelzang NJ; Trump DL; deVere White RW; Sarosdy MF; Wood DP; Raghavan D; Crawford ED
    N Engl J Med; 2003 Aug; 349(9):859-66. PubMed ID: 12944571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group.
    Splinter TA; Scher HI; Denis L; Bukowski R; Simon S; Klimberg I; Soloway M; Vogelzang NJ; van Tinteren H; Herr H
    J Urol; 1992 Mar; 147(3):606-8. PubMed ID: 1538438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.
    Koch MO; Coussens D
    Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
    Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
    Wei CH; Hsieh RK; Chiou TJ; Chen KK; Chang LS; Chen PM
    J Urol; 1996 Jan; 155(1):118-21. PubMed ID: 7490806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
    Higano CS; Tangen CM; Sakr WA; Faulkner J; Rivkin SE; Meyers FJ; Hussain M; Baker LH; Russell KJ; Crawford ED;
    Cancer; 2008 May; 112(10):2181-7. PubMed ID: 18404692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic preoperative chemotherapy with cisplatin, methotrexate and vinblastine for locally advanced bladder cancer: local tumor response and early followup results.
    Maffezzini M; Torelli T; Villa E; Corrada P; Bolognesi A; Leidi GL; Rigatti P; Campo B
    J Urol; 1991 Apr; 145(4):741-3. PubMed ID: 2005692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.